Current stage-Stage IV Posts on Medivizor
Navigation Menu

Current stage-Stage IV Posts on Medivizor

Evaluating the effectiveness and safety of taxanes combined with chemotherapy in patients with advanced triple negative breast cancer.

Evaluating the effectiveness and safety of taxanes combined with chemotherapy in patients with advanced triple negative breast cancer.

Posted by on May 24, 2023 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of taxanes combined with chemotherapy in patients with advanced triple-negative breast cancer (TNBC). This study concluded that the combination of taxanes and chemotherapy is effective with manageable side effects in these patients. Some background TNBC is a subtype of BC that tests...

Read More

Evaluating the safety and effectiveness of nivolumab and relatlimab before surgery in patients with resectable melanoma

Evaluating the safety and effectiveness of nivolumab and relatlimab before surgery in patients with resectable melanoma

Posted by on Apr 15, 2023 in Melanoma | 0 comments

In a nutshell The study evaluated the safety and effectiveness of relatlimab (Opdualag) and nivolumab (Opdivo) combination therapy before surgery in patients with stages III and IV resectable melanoma. The study concluded that the relatlimab and nivolumab combination was safe and effective in these patients. Some background...

Read More

Which sequence of treatment should be given first- immunotherapy or targeted therapy for patients with BRAF-mutated metastatic melanoma?

Which sequence of treatment should be given first- immunotherapy or targeted therapy for patients with BRAF-mutated metastatic melanoma?

Posted by on Mar 26, 2023 in Melanoma | 0 comments

In a nutshell This study evaluated which sequence of treatment should be given first – immunotherapy or targeted therapy – for the most clinical benefit in patients with BRAF-mutated metastatic melanoma. The data showed that immunotherapy followed by targeted therapy significantly improved survival outcomes in these patients. Some background...

Read More

Evaluating the effectiveness of chemotherapy before surgery for patients with colorectal cancer liver metastases.

Evaluating the effectiveness of chemotherapy before surgery for patients with colorectal cancer liver metastases.

Posted by on Mar 5, 2023 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness of chemotherapy given before surgery (neoadjuvant chemotherapy; NAC) for the treatment of patients with colorectal cancer liver metastasis (CRLM) at high risk. The data showed that NAC improved the overall survival of these patients. Some background Colorectal cancer (CRC) is one of the most common...

Read More

Evaluating the effectiveness and safety of immune checkpoint inhibitors either alone or in combination for the treatment of advanced malignant melanoma.

Evaluating the effectiveness and safety of immune checkpoint inhibitors either alone or in combination for the treatment of advanced malignant melanoma.

Posted by on Mar 5, 2023 in Melanoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of immune checkpoint inhibitors (ICIs) either alone or in combination for the treatment of patients with advanced melanoma. The data showed that nivolumab (Opdivo) and ipilimumab (Yervoy) combination therapy was more effective than nivolumab or ipilimumab alone for the treatment of...

Read More

Evaluating the effectiveness of abemaciclib alone or in combination with tamoxifen in patients with HR+, HER2– metastatic breast cancer resistant to hormone therapy.

Evaluating the effectiveness of abemaciclib alone or in combination with tamoxifen in patients with HR+, HER2– metastatic breast cancer resistant to hormone therapy.

Posted by on Jan 8, 2023 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness of abemaciclib (Verzenio) alone or in combination with tamoxifen (Nolvadex) in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (BC) resistant to hormone therapy. The data showed that abemaciclib in combination with tamoxifen was more effective in improving...

Read More

Evaluating the effectiveness and safety of anlotinib as a third-line treatment in patients with advanced NSCLC.

Evaluating the effectiveness and safety of anlotinib as a third-line treatment in patients with advanced NSCLC.

Posted by on Dec 31, 2022 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of anlotinib (AL3818) as a third-line treatment in patients with advanced non-small cell lung cancer (NSCLC). The data showed that anlotinib as a third-line treatment was effective with manageable side effects in these patients. Some background NSCLC is the most common form of lung...

Read More

Comparing the effectiveness of TAS-102 versus regorafenib for the treatment of patients with metastatic colorectal cancer.

Comparing the effectiveness of TAS-102 versus regorafenib for the treatment of patients with metastatic colorectal cancer.

Posted by on Dec 9, 2022 in Colorectal cancer | 0 comments

In a nutshell This study compared the effectiveness of TAS-102 (Lonsurf; trifluridine-tipiracil) versus regorafenib (Stivarga) for the treatment of patients with metastatic colorectal cancer (mCRC). The data showed that TAS-102 had better oncologic outcomes than regorafenib in these patients. Some background Colorectal cancer (CRC) is one of the...

Read More

Evaluating the effectiveness and safety of ramucirumab and pembrolizumab versus standard of care in previously treated patients with advanced NSCLC.

Evaluating the effectiveness and safety of ramucirumab and pembrolizumab versus standard of care in previously treated patients with advanced NSCLC.

Posted by on Dec 9, 2022 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety outcomes of ramucirumab (Cyramza) and pembrolizumab (Keytruda) versus standard of care (SOC) in previously treated patients with advanced non-small cell lung cancer (NSCLC). The data showed that ramucirumab and pembrolizumab significantly improved overall survival compared with SOC in...

Read More

Evaluating the health-related quality of life outcomes of second-line chemotherapy combined with either bevacizumab or cetuximab in patients with advanced colorectal cancer.

Evaluating the health-related quality of life outcomes of second-line chemotherapy combined with either bevacizumab or cetuximab in patients with advanced colorectal cancer.

Posted by on Dec 4, 2022 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the health-related quality of life (HR-QoL) outcomes of second-line chemotherapy combined with either bevacizumab (Avastin) or with cetuximab (Erbitux) in patients with advanced colorectal cancer with wild-type KRAS. This study concluded that the HR-QoL outcomes were similar with both treatments in these...

Read More

Comparing the effectiveness and safety of combined therapy of pertuzumab with trastuzumab versus single trastuzumab therapy in patients with HER2-positive advanced breast cancer

Comparing the effectiveness and safety of combined therapy of pertuzumab with trastuzumab versus single trastuzumab therapy in patients with HER2-positive advanced breast cancer

Posted by on Nov 14, 2022 in Breast cancer | 0 comments

In a nutshell The study compared the effectiveness and safety of pertuzumab (Perjeta) and trastuzumab (Herceptin) combined therapy with trastuzumab alone in patients with HER2-positive (HER2+) advanced breast cancer (BC). The study found that the combined therapy was more effective and well tolerated compared to single therapy in...

Read More

Evaluating the effectiveness and safety of elacestrant versus standard hormonal therapy in patients with ER+/HER2- advanced BC.

Evaluating the effectiveness and safety of elacestrant versus standard hormonal therapy in patients with ER+/HER2- advanced BC.

Posted by on Oct 7, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of elacestrant (RAD1901) versus standard hormonal therapy in patients with estrogen receptor-positive (ER+) and HER2-negative (HER2-) advanced breast cancer (BC). The data showed that elacestrant significantly improved survival without cancer worsening with manageable side effects in these...

Read More